NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: ZeroFox has agreed to be acquired by Havel ...

Catalent (CTLT) shares rallied 9.7% in the last trading session to close at $59.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.2% gain over the past four weeks.The sharp upsurge in Catalent's shares can be attributed to the announcement of a deal where the company will be acquired by Novo Holdings for $63.50 per share in cash. The deal puts an enterprise value of $16.5 billion on Catalent.This maker o ...

Shares of Catalent (CTLT 9.74%) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent company of Novo Nordisk (NVO 4.01%).Novo Nordisk is bringing Catalent under its wingIn a press release Monday, Catalent announced it had agreed to be acquired by Novo Holdings for $63.50 per share in cash -- a 16.5% premium from Friday's closing price and a nearly 48% premium to its 60-day volume-weighted average pri ...

The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5 billion. The merger will help Novo meet strong demand for weight-loss drug Wegovy, increasing its filling capacity starting in 2026. On the charts, CTLT has been chopping higher since mid-November. Today's jump still isn't enough to close its April bear gap, though, which occurred after a Danaher (DHR) takeover ...

KEY TAKEAWAYSShares of Catalent soar on news Novo Holdings, the majority owner of Novo Nordisk, is acquiring the syringe maker for $16.5 billion in cash.The deal represents a 16.5% premium over Catalent's pre-announcement stock price Friday.The acquisition expands Novo Nordisk's production capacity and supply flexibility, particularly for its Wegovy weight loss drug.Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo No ...

Catalent (NYSE:CTLT) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE:NVO) parent Novo Holdings for $16.5 billion.The transaction will have Novo Holdings paying $63.50 per share in cash for CTLT stock. That represents a premium of 16.5% over the closing price for Catalent’s stock on Friday. It’s also a 47.5% premium to the 60-day volume-weighted average price of the shares.After the deal closes, Novo Holdings intends to sell three of Catalent’s 60 locations to ...

Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023.Novo Nordisk's parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection Wegovy and diabetes shot Ozempic. Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy. As part of the d ...

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)’s controlling shareholder was to buy the firm for US$16.5 billion. Novo Holdings, which owns a majority stake in the weight-loss drug maker, unveiled the takeover on Monday, which includes assumed debt and, at US$63.50 a share, represents a 16.5% premium on Catalent’s Friday closing price. Novo Nordisk (NYSE:NVO), Europe’s largest company by market cap, will take control of t ...

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it’s buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday’s close. The deal is a 39% premium to Catalent’s close before it announced a strategic review. Novo will sell three fill-finish sites to Novo Nordisk shortly after the deal closes. Catalent investor Elliott Investment Management said it supports the deal. ...

COPENHAGEN, Denmark & SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise val ...